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Introduction {#sec1}
============

The introduction of the human induced pluripotent stem cell (hiPSC) technology ([@bib35]) coupled with improved methods for cardiomyocyte differentiation ([@bib3], [@bib27]) brought a unique value to the fields of cardiac disease modeling ([@bib2], [@bib13], [@bib25], [@bib26], [@bib30], [@bib34]) and drug testing ([@bib21], [@bib31], [@bib33], [@bib42]). In the field of cardiac electrophysiology, most studies examined the electrical properties of the hiPSC-derived cardiomyocytes (hiPSC-CMs) at the single-cell level, focusing primarily on action potential (AP) and ionic current characteristics. Only a few studies have utilized multicellular hiPSC-based cardiac tissue models to evaluate conduction and arrhythmogenesis ([@bib8], [@bib16], [@bib18], [@bib19]).

Traditional methodologies used for studying conduction in cardiomyocyte cultures include multielectrode extracellular recordings ([@bib39]), which may be limited in terms of spatial resolution and degree of complexity of the information gained, or optical mapping ([@bib9]). The latter approach utilizes voltage-sensitive dyes (VSDs) to follow changes in membrane potential ([@bib23], [@bib24]). These indicators, although of great utility, can cause phototoxicity and hamper the ability to obtain long-term and repeated recordings.

To overcome the aforementioned challenges, we propose to combine the hiPSC technology, two-dimensional (2D) cardiac tissue models, and genetically encoded voltage indicators (GEVIs), such as ArcLight ([@bib20], [@bib31]), VSFP-CR ([@bib5]), CaViar ([@bib6]), and VSFP2.3 ([@bib22]), for probing membrane potentials. Specifically, we chose to focus on ArcLight and hypothesized that the generated ArcLight-expressing hiPSC-derived cardiac cell sheets (hiPSC-CCSs) will allow gaining high-resolution information regarding tissue conduction and repolarization in both acute and long-term studies. Following establishment of this unique multicellular model, we aimed to evaluate its potential for drug testing using agents known to alter conduction and/or repolarization with specific emphasis on studying the mechanisms of drug-induced arrhythmias at the tissue level. Finally, we aimed to evaluate the biophysical properties of reentrant arrhythmias (spiral waves) induced in this model through either a drug-related pro-arrhythmia mechanism or following programmed electrical stimulation and to test the efficacy of clinically relevant therapeutic interventions.

Results {#sec2}
=======

Generation of ArcLight-Expressing hiPSC-CCSs {#sec2.1}
--------------------------------------------

ArcLight-expressing hiPSCs from a stable transgenic line established in our laboratory ([@bib31]) were differentiated into the cardiac lineage using a modified directed small-molecule monolayer-based differentiation system ([@bib3]). Following differentiation, beating monolayers, containing ≥85% cardiomyocytes ([Figure S1](#mmc1){ref-type="supplementary-material"}A), were enzymatically dissociated and seeded as circular homogeneous hiPSC-CCSs ([Figure S1](#mmc1){ref-type="supplementary-material"}B).

A series of experimental calibration and optimization steps were then performed to determine the optimal seeding density required to obtain hiPSC-CCSs, which will be highly confluent but without evidence for cell death due to improper diffusion. The optimal approach, according to these studies, consisted of using only highly enriched early-stage differentiated cardiomyocytes (\>85% cardiac troponin T positive, 8--14 days post differentiation). Tissues were generated from single-cell suspensions, derived following enzymatic dissociation and the use of a 100 μm cell strainer, at a seeding density of 38,000--56,000 cells/mm^2^. We chose to generate hiPSC-CCSs with a ∼0.5 cm diameter, as this size was sufficient for monitoring electrical propagation, measuring local conduction velocities (CVs), and inducing arrhythmias.

We next performed cell content analysis by enzymatically digesting hiPSC-CCSs at different developmental stages. This time-series analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}C) revealed a major drop in cell content between day 0 (d0) and d1, and a relatively stable cell content after d6--10. The final cell count was ∼400,000 cells/hiPSC-CCS, which was sufficient to achieve homogeneous tissues without any structural discontinuities in 80%--90% of independent sessions.

Immunostaining of sarcomeric α-actinin and connexin 43 (Cx43) confirmed the presence of high-density electrically coupled cardiomyocytes arranged in an isotropic pattern within the hiPSC-CCSs ([Figure S1](#mmc1){ref-type="supplementary-material"}). Structural characterization using three-dimensional reconstruction ([Figures S1](#mmc1){ref-type="supplementary-material"}D--S1F) and orthogonal views ([Figure S2](#mmc1){ref-type="supplementary-material"}G) revealed that the final tissues consisted of approximately four cell layers (range, 3--7; n = 13 from four independent experiments) with a thickness of 19.1 ± 8.4 μm.

Comparison of ArcLight and Di-4-ANBDQBS-Based Optical Mapping {#sec2.2}
-------------------------------------------------------------

We hypothesized that GEVIs can be utilized for long-term and repeated electrophysiological phenotyping without affecting cell viability. The ability of ArcLight to evaluate human cardiomyocyte AP morphology and duration was already demonstrated at the cellular level ([@bib20], [@bib31]) but has not been utilized at the tissue level to evaluate conduction. One potential limitation of GEVIs in general and ArcLight specifically is their relatively slow kinetics ([@bib15]), a property that may hinder their potential use for activation mapping. To evaluate whether, despite this limitation, ArcLight imaging can still be used to reliably evaluate tissue conduction, we compared the results of ArcLight-based activation mapping with similar maps obtained using conventional VSD-based mapping over a wide array of conditions ([Figures 1](#fig1){ref-type="fig"} and [S2--S4](#mmc1){ref-type="supplementary-material"}).Figure 1ArcLight versus Di-4-ANBDQBS: Mapping Comparison(A and B) Activation (A) and APD~80~ (B) maps of the same ArcLight-hiPSC-CCS generated from analysis of Di-4-ANBDQBS (top) and ArcLight (bottom) signals during spontaneous activity, 0.5 Hz and 1 Hz pacing frequencies. Single isochrone: 20 ms. Scale bars: 5 mm.(C) Representative traces of Di-4-ANBDQBS (red) and ArcLight (green) optical APs recorded from the same region of interest (ROI) (3 × 3 pixels).(D) Correlation between MLCVs values, as derived from ArcLight and Di-4-ANBDQBS activation maps in the same cultures. Notice the high correlation (R^2^ = 0.9847, n = 25 from four independent experiments) in MLCVs measurements made by the two methods.(E) Similar comparison of the mean APD~80~ as measured from ArcLight and Di-4-ANBDQBS recordings (R^2^ = 0.8966, n = 25 from four independent experiments).See also [Figures S1--S4](#mmc1){ref-type="supplementary-material"} and [Video S1](#mmc2){ref-type="supplementary-material"}.

ArcLight-hiPSC-CCSs (6--35 days post plating) were loaded with the VSD, Di-4-ANBDQBS, paced at variable cycle lengths (CLs, 300--2,000 ms) and alternatingly imaged by manual interchanging between two filter sets, one for obtaining ArcLight optical signals and the other for Di-4-ANBDQBS signals ([Figure S2](#mmc1){ref-type="supplementary-material"}A). These studies verified the development of a functional syncytium, enabled monitoring of AP wave propagation ([Video S1](#mmc2){ref-type="supplementary-material"}), and allowed construction of detailed activation and APD maps using both ArcLight and Di-4-ANBDQBS signals ([Figures 1](#fig1){ref-type="fig"}, [S2](#mmc1){ref-type="supplementary-material"}, and [S3](#mmc1){ref-type="supplementary-material"}).

We found that the slower kinetics of ArcLight affected mostly the final portion of phase 0 of the AP ([Figures 1](#fig1){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}E). Consequentially, by defining the local activation time (LAT) as the time point of the maximum first derivative of the recorded signal at each pixel ([Figures 1](#fig1){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}E), we were able to construct ArcLight-based activation maps that did not differ from those generated using Di-4-ANBDQBS mapping ([Figures 1](#fig1){ref-type="fig"}A, [S2](#mmc1){ref-type="supplementary-material"}, and [S3](#mmc1){ref-type="supplementary-material"}). This was also confirmed quantitatively, as a high correlation (R^2^ = 0.985, [Figure 1](#fig1){ref-type="fig"}D, n = 25) was found between the mean local conduction velocities (MLCV) measured from the corresponding ArcLight and Di-4-ANBDQBS maps across a wide range of MLCV values. The agreement between ArcLight and Di-4-ANBDQBS mapping was also validated when using different signal-acquisition rates (260 and 520 frames/s, [Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). Similarly, the average APD~80~ (APD at 80% repolarization) values measured by ArcLight correlated (R^2^ = 0.897, [Figure 1](#fig1){ref-type="fig"}E, n = 25) with the measurements derived from Di-4-ANBDQBS recordings over a wide range of values. Notice that, despite this high correlation, ArcLight APD~80~ values tended to overestimate APD as compared with Di-4-ANBDQBS recordings ([Figures 1](#fig1){ref-type="fig"}B and 1E).

ArcLight Displays Decreased Phototoxicity {#sec2.3}
-----------------------------------------

We next attempted to compare ArcLight- with VSD-based mapping in regards to signal-to-noise ratio (SNR) and phototoxicity. In a series of preliminary studies, we found that the optimal loading conditions of Di-4-ANBDQBS were 60 μg/mL for 20 min. Using these conditions, we noted that the SNR values of Di-4-ANBDQBS were comparable with that of ArcLight (p \> 0.05, n = 9, [Figure S4](#mmc1){ref-type="supplementary-material"}A). This finding was verified using additional four different formulas previously utilized to calculate SNR (data not shown).

In order to compare the potential cytotoxic effects of both indicators, we illuminated a focused area within the ArcLight-hiPSC-CCSs for 10 min (central portion in [Figure S4](#mmc1){ref-type="supplementary-material"}B). These studies were conducted in ArcLight-hiPSC-CCSs that were also loaded with Di-4-ANBDQBS and compared with hiPSC-CCSs expressing ArcLight alone or Di-4-ANBDQBS alone ([Figure S4](#mmc1){ref-type="supplementary-material"}C). ArcLight-hiPSC-CCSs were also exposed to red illumination to rule out the contribution of this factor. Our results show a significant decline in the optical signals in the two groups containing Di-4-ANBDQBS (\"ArcLight + Di-4-ANBDQBS″ and \"Di-4-ANBDQBS alone\"; [Figure S4](#mmc1){ref-type="supplementary-material"}C). Importantly, the decline in optical signal in the ArcLight + Di-4-ANBDQBS group was not restricted to Di-4-ANBDQBS signal but was also present in ArcLight recordings ([Figure S4](#mmc1){ref-type="supplementary-material"}C). In contrast, the decline in the optical signal was minimal in the \"ArcLight alone\" hiPSC-CCSs groups exposed to either blue or red illumination ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

The aforementioned results suggest a potential phototoxic effect induced by Di-4-ANBDQBS. To test this hypothesis, we illuminated only the central portion of hiPSC-CCSs ([Figure S4](#mmc1){ref-type="supplementary-material"}B) for 20 min and then labeled the tissues with DAPI. We then quantified the DAPI signal (as a marker of membrane damage or cell death) in the central illuminated area and normalized it by the DAPI signal in the non-illuminated peripheral area (center/periphery DAPI ratio). As shown in [Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D, an increased toxicity at the illuminated center was only observed in the two groups loaded with Di-4-ANBDQBS (ArcLight + Di-4-ANBDQBS and Di-4-ANBDQBS alone) and was lacking in the blue or red-illuminated ArcLight alone group and in the control hiPSC-CCS group (lacking both reporters) ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). These results suggest that ArcLight-based imaging may be less cytotoxic and therefore more suitable for long-term and repeated tissue phenotyping.

Repeated Long-Term Analysis of the ArcLight-hiPSC-CCSs {#sec2.4}
------------------------------------------------------

To test the hypothesis that ArcLight-based optical mapping can allow repeated and long-term analysis, we followed the electrical remodeling process of the ArcLight-hiPSC-CCSs for more than a month. [Figures 2](#fig2){ref-type="fig"}A and 2B depict changes in mean APD~80~ and MLCV values respectively, at each time point, for the seven cultures studied while paced at 1 Hz. These long-term studies revealed gradual shortening of mean APD values ([Figure 2](#fig2){ref-type="fig"}A, p \< 0.0001, n = 7) and a gradual increase in CV values ([Figure 2](#fig2){ref-type="fig"}B), with the fastest CVs peaking at d16--20 (p \< 0.0001, n = 7) and then slightly declining (p \> 0.05) at d26--35.Figure 2Effects of Culture Time, Pacing Frequency, and Repeated Drug Applications on APD~80~ and CV Measurements(A and B) Summary of mean APD~80~ (A) and MLCV (B) values as a function of culture time in ArcLight-hiPSC-CCSs (repeated-measurements one-way ANOVA followed by Tukey post-hoc analysis, n = 7 from three independent experiments).(C) Summary of changes in the normalized APD~80~ values over time in three hiPSC-CCSs during repeated drug experiments (dofetilide and quinidine).(D) Restitution curves summarizing the changes in MLCV and mean APD~80~ values in hiPSC-CCS (6--10 days post plating) as function of pacing cycle length (repeated-measurements one-way ANOVA followed by Tukey post-hoc analysis, n = 7 and 6 respectively, from three independent experiments).Values are presented as means ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, and ^∗∗∗∗^p \< 0.0001. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

To address the mechanisms underlying the CV changes over time, we focused on Cx43 expression (as a surrogate for intercellular coupling) and on Na^+^ current recordings (as a surrogate for membrane excitability). As shown in the western blot analysis in [Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B, we did not observe any consistent changes in Cx43 expression between hiPSC-CCSs at 6--10 days versus 16--20 days. Next, we conducted voltage-clamp studies to measure I~Na+~ from single dispersed hiPSC-CMs, derived from hiPSC-CCSs at 6 days or 20 days post plating. As depicted in the current-voltage curves in [Figure S5](#mmc1){ref-type="supplementary-material"}C, cardiomyocytes derived from hiPSC-CCSs at d20 displayed significantly higher peak-current densities (106.5 ± 13.2 versus 70.1 ± 9.9 pA/pF, p \< 0.01, n = 15 and 13).

Finally, we aimed to test the suitability of ArcLight-hiPSC-CCSs for repeated pharmacological studies by conducting multiple recordings from the same culture over several days and applying different repolarization-altering drugs at each day (10 nmol/L dofetilide and 5 μmol/L quinidine). The results demonstrate APD~80~ prolongation in response to each compound followed by recovery to baseline values following drug washout ([Figure 2](#fig2){ref-type="fig"}C).

Pharmacological and Pacing Studies {#sec2.5}
----------------------------------

We next aimed to monitor the effects of different interventions on the electrophysiological properties of the hiPSC-CCSs. We first tested the effects of altering pacing frequency (1, 1.25, 1.67, 2 Hz) on the tissues\' AP (APD) and conduction (MLCV) properties. Notice in the resulting restitution plots ([Figure 2](#fig2){ref-type="fig"}D) the expected APD shortening (p \< 0.01, n = 6) and CV slowing (p \< 0.0001, n = 7) with higher pacing frequencies.

We next tested the effects of different drugs on the electrical properties of the hiPSC-CCSs. The drugs tested included agents known to slow conduction via two different mechanisms: (1) carbenoxolone (50 μmol/L), a gap-junction blocker; and (2) lidocaine (1--300 μmol/L), a class Ib antiarrhythmic agent that blocks the fast voltage-gated Na^+^ channels. Both agents (n = 5) significantly slowed conduction in all cultures, as depicted in the activation maps presented prior to and after drug application ([Figure 3](#fig3){ref-type="fig"}A, left panels). Note also the typical dose-response effect of lidocaine on MLCV ([Figure 3](#fig3){ref-type="fig"}A, middle-right panels).Figure 3Pharmacological Effects on Repolarization and Conduction(A) Representative activation maps (left and middle) and dose-response curves (right) of CV slowing drugs: carbenoxolone (50 μmol/L, n = 5 from three independent experiments, paired t test), lidocaine (1, 3, 10, 30, 100, and 300 μmol/L), and quinidine (0.1, 0.3, 1, 3, 10, and 30 μmol/L). Multiple comparisons were made using one-way ANOVA followed by Tukey post-hoc analysis, both n = 5 from four and three independent experiments, respectively.(B) Representative APD~80~ maps (left and middle) and dose-response curves (right) of APD prolonging drugs: dofetilide (0.3, 1, 3, 10, 30, and 100 nmol/L) and quinidine (0.1, 0.3, 1, 3, 10, and 30 μmol/L). Multiple comparisons made using one-way ANOVA followed by Tukey post-hoc analysis, both n = 5 from three independent experiments).Scale bars: 5 mm. Values are presented as means ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 and ^∗∗∗∗^p \< 0.0001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

We next tested the ability to detect repolarization changes by applying dofetilide (0.3--100 nmol/L), a class III antiarrhythmic agent that blocks I~Kr~. As expected, dofetilide led to significant APD prolongation, as depicted in the APD~80~ map example ([Figure 3](#fig3){ref-type="fig"}B, top-left panels) and in the plot summarizing the dose-response changes in mean APD~80~ for all cultures ([Figure 3](#fig3){ref-type="fig"}B, top-right panel; n = 5).

Finally, we tested the effects of quinidine (0.1--30 μmol/L), a Na^+^ channel blocker with additional non-specific potassium channels blocking activity. The resulting activation ([Figure 3](#fig3){ref-type="fig"}A, bottom-left panels) and APD~80~ ([Figure 3](#fig3){ref-type="fig"}B, bottom-left panels) maps and the corresponding dose-response curves (bottom-right panels, n = 5) revealed the dual effect of quinidine, both slowing conduction and prolonging APD in the hiPSC-CCSs.

Modeling Reentrant Arrhythmia (Spiral Waves) {#sec2.6}
--------------------------------------------

We next aimed to evaluate whether ArcLight imaging could go beyond assessment of conduction in the hiPSC-CCSs and also be used to detect, monitor, and study reentrant arrhythmias. To this end, we aimed to induce arrhythmias in the hiPSC-CCSs through a systematic electrical stimulation approach: starting by an increase in stimulation frequency followed by burst pacing and finally direct current injection ([Video S2](#mmc3){ref-type="supplementary-material"}). Using this induction protocol, we were able to induce reentrant arrhythmias in 30% of the hiPSC-CCSs and to monitor the resulting rotors\' activities using ArcLight optical signals. Once initiated, the rotors (spiral waves) were highly stable and were associated with a significant increase (p \< 0.05) in the frequency of activation (CL = 476 ± 237 ms) as compared with baseline spontaneous activity (CL = 2,853 ± 1,114 ms, n = 5).

The propagation of the spiral waves could be followed by ArcLight optical mapping, either as dynamic displays depicting the changes in ArcLight fluorescence ([Video S3](#mmc4){ref-type="supplementary-material"}, upper panels) or by constructing detailed activation maps ([Figure 4](#fig4){ref-type="fig"}A). An alternative strategy to characterize complex reentrant activity is phase mapping ([@bib7], [@bib11], [@bib14], [@bib28]). The constructed phase maps, generated by mathematical processing of the optical signals, could be used to characterize the spiral waves either as snapshots ([Figure 4](#fig4){ref-type="fig"}B) or as dynamic displays ([Video S3](#mmc4){ref-type="supplementary-material"}, lower-panels). This approach makes it possible to follow the propagation of the rotor\'s wave front, its singularity point (SP) (the point where all phases conjoin, depicted as black dots in [Figure 4](#fig4){ref-type="fig"}B and [Video S3](#mmc4){ref-type="supplementary-material"}), and its meandering path ([Figure 4](#fig4){ref-type="fig"}C). Such analysis also allows quantification of various spiral wave biophysical properties, including the rotor\'s frequency (2.53 ± 1.14 Hz, n = 5, [Figure 4](#fig4){ref-type="fig"}D), radius (inversely proportional to curvature, 2.59 ± 1.48 mm; [Figure 4](#fig4){ref-type="fig"}D), and the spatial quantification of SP meandering (1.34 ± 1.50 mm; [Figures 4](#fig4){ref-type="fig"}C and 4D).Figure 4Analysis of Spiral Waves (Rotors)(A) Activation maps of the induced rotors in three ArcLight-hiPSC-CCSs. Single isochrones: 20 ms.(B) Snapshots of phase maps of the same rotors. Colors represent phase, as in the color bar and the colored signal (right). Singularity points (SPs) are indicated as black dots. Black and white lines indicate the wave fronts and tails respectively. Red lines extending from the SP to the wave front, indicate radiuses of the curvatures.(C) Trajectory of SP meandering for each of the three rotors; total pathway of six SP steps over one rotation cycle.(D) Summary of rotating frequency (2.526 ± 1.141 Hz), rotor radius (2.594 ± 1.48 mm; error bars represent SEM), and SP meandering pathway (1.342 ± 1.505 mm) of five rotors (from three independent experiments).Scale bars: 5 mm. See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Videos S2](#mmc3){ref-type="supplementary-material"} and [S3](#mmc4){ref-type="supplementary-material"}.

We next evaluated whether clinically relevant maneuverers such as electrical cardioversion and overdrive pacing can terminate such reentrant arrhythmias. To allow field electrical cardioversion, we placed bipolar electrodes at opposing borders of the hiPSC-CCSs ([Figure S2](#mmc1){ref-type="supplementary-material"}D) and applied a 50 ms biphasic pulse over the entire tissue. This resulted in arrhythmia termination in seven out of seven cultures studied, as shown in [Figures 5](#fig5){ref-type="fig"}A--5C and [Video S4](#mmc5){ref-type="supplementary-material"}.Figure 5Spiral Waves Termination by Electrical Cardioversion and Overdrive Pacing(A) Fluorescent trace from one area (red) in an ArcLight-hiPSC-CCS exhibiting stable spiral wave.(B and C) Phase (upper panel) and activation (lower panel) maps before (B) and after (C) electric cardioversion.(D and E) Fluorescence traces from two points, 1 (red) and 2 (blue), in an ArcLight-hiPSC-CCS exhibiting stable spiral wave. Vertical marks denote timing of pacing pulses.(F--I) Phase maps during the arrhythmia (F), during overdrive pacing (G and H), and after recovery to spontaneous normal activity (I). Black trajectories depict the meandering of the SP during each time period.(J) Cumulative arrhythmia conversion rates in relation to rotor CL minus pacing CL (n = 7 from four independent experiments).Scale bars: 5 mm. See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Videos S4](#mmc5){ref-type="supplementary-material"} and [S5](#mmc6){ref-type="supplementary-material"}.

As for overdrive pacing, we performed point stimulation of the hiPSC-CCSs at rates faster than arrhythmia\'s CL, as shown in [Figures 5](#fig5){ref-type="fig"}D--5I and [Video S5](#mmc6){ref-type="supplementary-material"}. [Figures 5](#fig5){ref-type="fig"}D and 5E show the fluorescent signals recorded from two sites in a hiPSC-CCS with stable rotor activity (phase map in [Figure 5](#fig5){ref-type="fig"}F) with a CL of 350 ms. Next, the electrical wave initiated by the high-frequency pacing (CL = 300 ms) was able to drive the reentrant activity to the top edge of the hiPSC-CCS ([Figure 5](#fig5){ref-type="fig"}G, note the black trace and white arrow showing the migration path of the rotor\'s SP). Occasionally, as shown in this example, new rotors emerged during overdrive pacing, which were also driven to the edge of the culture ([Figure 5](#fig5){ref-type="fig"}H), leading eventually to arrhythmia termination and restoration of normal activity ([Figure 5](#fig5){ref-type="fig"}I). [Figure 5](#fig5){ref-type="fig"}J summarizes the cumulative cardioversion rate in all hiPSC-CCSs studied following sequential increases in pacing frequency (defined as \"rotor CL-pacing CL″), leading to termination of reentrant activity in six out of seven cultures studied.

Drug-Induced Pro-arrhythmia (Torsades de Pointes in the Dish) {#sec2.7}
-------------------------------------------------------------

Recent studies demonstrated the potential of hiPSC-CMs in the field of safety pharmacology by detecting drug-induced APD prolongation at the cellular level ([@bib20], [@bib21], [@bib31], [@bib33], [@bib42]). Nevertheless, APD prolongation and even development of early after-depolarizations (EADs) and triggered activity (TA) are not sufficient for development of the relevant clinical arrhythmia (torsades de pointes \[TdP\]), which requires also the presence of an abnormal substrate at the tissue level ([@bib1]). To study the process of drug-induced arrhythmias also at the tissue level we treated the hiPSC-CCSs with a high dose of dofetilide (50 nmol/L, [Figure 6](#fig6){ref-type="fig"}). This led to significant and diffuse APD prolongation throughout the culture, eventually causing sustained reentrant arrhythmias in five out of 12 examined hiPSC-CCSs.Figure 6Fluorescence Time Lapse of Dofetilide-Induced Arrhythmogenesis(A) Three ROIs are highlighted: (1) region with no detected triggered activity, (2) region with EAD/TA that did not develop to subsequent arrhythmia, and (3) region with TA that deteriorated into stable arrhythmia. Black scale bar: 2 s. White scale bar: 5 mm. Color scale bar represents fluorescence intensity (corresponding to voltage changes).(B--K) Fluorescence time-lapse snapshots describing dofetilide-induced arrhythmogenesis. Note that following propagation of the first activation wave-front (B--C) and EAD/TA developed that failed to propagate and did not induce a stable arrhythmia (D). In contrast, following the second activation wave (E--F), a TA developed (G) that caused \"figure-of-eight\" reentry (H), unidirectional conduction block and eventually the development of a stablespiral wave (I--K).See also [Video S6. Dofetilide-Induced Arrhythmogenesis \#1, Related to Figures 6 and 7 and Videos S7 and S8](#mmc7){ref-type="supplementary-material"}, [Video S7. Dofetilide-Induced Non-propagating EADs, Related to Figures 6 and 7 and Videos S6, S8, and S9](#mmc8){ref-type="supplementary-material"}, [Video S8. Dofetilide-Induced Propagating TA, Related to Figures 6 and 7 and Videos S6, S7, and S9](#mmc9){ref-type="supplementary-material"}, [Video S9. Dofetilide-Induced Arrhythmogenesis \#2, Related to Figures 6 and 7 and Videos S6--S8](#mmc10){ref-type="supplementary-material"}.

By performing long-term mapping of ArcLight-hiPSC-CCSs, we were able to detect the cascade of events that led to the establishment of stable dofetilide-induced arrhythmia ([Video S6](#mmc7){ref-type="supplementary-material"} and [Figure 6](#fig6){ref-type="fig"}). Notice in both the video and the resulting snapshots of the fluorescent (\"potential\") maps, the development of EADs/TA in localized spots (high voltage, red signal) within the hiPSC-CCS. Note that during the first activation, while APD was prolonged throughout the culture, an EAD could be detected only at one area at the center of the culture (localized increase in membrane potential \[red area\] at recording site 2 in [Figure 6](#fig6){ref-type="fig"}D). This EAD could not be propagated since all areas surrounding it were still relatively depolarized (homogeneous green/yellow). In the next beat, an EAD/TA developed at a different site (site 3 in [Figure 6](#fig6){ref-type="fig"}G). Due to the localized heterogeneity in the tissue, with neighboring cells already being repolarized (adjacent blue-purple areas in [Figure 6](#fig6){ref-type="fig"}G), this new ectopic activity could be propagated, generating an initial figure-of-eight reentry ([Figures 6](#fig6){ref-type="fig"}G--6I) before deteriorating into stable rotor-like activity ([Figures 6](#fig6){ref-type="fig"}I--6K).

Prevention of Dofetilide-Induced Pro-arrhythmia {#sec2.8}
-----------------------------------------------

To evaluate the potential role of clinically relevant treatments for TdP in our model, we tested the effects of rapid pacing and magnesium administration in preventing dofetilide-induced arrhythmias. To this end, we took advantage of the ability to study the same ArcLight-hiPSC-CCS over time and tested the incidence of arrhythmic activity following application of dofetilide alone as compared with dofetilide together with magnesium administration or rapid pacing. The electrical activity was closely monitored and resulting pro-arrhythmia was classified and scored as either non-propagating EADs/TA ([Video S7](#mmc8){ref-type="supplementary-material"}, arrhythmogenic score 1), isolated propagated TA ([Video S8](#mmc9){ref-type="supplementary-material"}, score 2), or stable reentrant activity (TdP, [Videos S6](#mmc7){ref-type="supplementary-material"} and [S9](#mmc10){ref-type="supplementary-material"}, score 3).

Application of dofetilide resulted in significant prolongation of APD ([Figures 7](#fig7){ref-type="fig"}A and 7B) and in the generation of non-propagated EADs/TA alone in one of six cultures studied, isolated TA in two specimens, and stable reentrant activity in an additional two cultures ([Figure 7](#fig7){ref-type="fig"}D, top panel). Pacing of the dofetilide-treated hiPSC-CCSs at relatively fast rates (CL: 800--1,000 ms) shortened APD and prevented all arrhythmic events (EAD, TA, or TdP), significantly lowering the arrhythmic risk score to 0 (p \< 0.01, n = 6, [Figures 7](#fig7){ref-type="fig"}D and 7E).Figure 7Prevention of Dofetilide-Induced Arrhythmogenicity by Rapid Pacing and Magnesium Sulfate(A) Summary of dofetilide and dofetilide + MgSO~4~ supplementation effects on APD~80~ (one-way ANOVA followed by Tukey post-hoc analysis, n = 6 from three independent experiments for each group).(B) Representative optical APs from ArcLight-hiPSC-CCS after treatment with dofetilide or dofetilide + MgSO~4~.(C) Optical APs from ArcLight-hiPSC-CCS showing arrhythmogenic activity (TA and EAD) at slow pacing frequencies (CL, 5,000 and 2,000 ms) and their suppression at higher pacing frequency (CL, 800 ms).(D) Summary of dofetilide-induced arrhythmogenicity in ArcLight-hiPSC-CCSs and its suppression by MgSO~4~ supplementation and rapid pacing.(E) Arrhythmogenicity scoring system and summary of MgSO~4~ supplementation and rapid pacing on ArcLight-hiPSC-CCSs\' arrhythmogenicity score (Kruskal-Wallis test followed by Dunn\'s multiple comparison, n = 6 from three independent experiments for each group).Values are presented as means ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01 and ^∗∗∗^p \< 0.001. See also [Video S6. Dofetilide-Induced Arrhythmogenesis \#1, Related to Figures 6 and 7 and Videos S7 and S8](#mmc7){ref-type="supplementary-material"}, [Video S7. Dofetilide-Induced Non-propagating EADs, Related to Figures 6 and 7 and Videos S6, S8, and S9](#mmc8){ref-type="supplementary-material"}, [Video S8. Dofetilide-Induced Propagating TA, Related to Figures 6 and 7 and Videos S6, S7, and S9](#mmc9){ref-type="supplementary-material"}, [Video S9. Dofetilide-Induced Arrhythmogenesis \#2, Related to Figures 6 and 7 and Videos S6--S8](#mmc10){ref-type="supplementary-material"}.

Co-administration of 2.1 mmol/L of MgSO~4~ with dofetilide also prevented APD prolongation in the hiPSC-CCSs ([Figures 7](#fig7){ref-type="fig"}A and 7B, p \< 0.01, n = 6). Magnesium also reduced arrhythmogenicity in the cultures with only two specimens developing dofetilide-induced EADs and none developing any propagated TA or TdP, significantly reducing the arrhythmogenicity score ([Figures 7](#fig7){ref-type="fig"}D and 7E).

Discussion {#sec3}
==========

The ability to derive hiPSC-CMs offers unique opportunities for cardiac regenerative medicine, disease modeling, and drug testing. In the cardiac electrophysiology field, most efforts have focused on studying the cellular properties of hiPSC-CMs, namely their AP properties and ionic current profile, with only limited studies evaluating the tissue electrical properties. However, fulfilling the unique potential of the hiPSC technology for studying more complex electrophysiological phenomena (conduction and reentry) and for evaluating long-term tissue remodeling processes and drug effects requires the development of multicellular models as well as methods for long-term, repeated, tissue phenotyping. To address these challenges, we combined hiPSC-CMs, GEVIs, and optical mapping technologies to establish a robust 2D cardiac tissue model for cardiac mapping. The established ArcLight-hiPSC-CCSs model enabled long-term and repeated phenotyping of the same cultures; detailed pharmacological studies evaluating drug effects on conduction, repolarization, and pro-arrhythmia mechanisms; and complex arrhythmia modeling focusing on the biophysical properties of rotors.

Two-dimensional rather than cellular models are important since they resemble more the native organization of cardiomyocytes within the heart and in parallel allow the induction and high-resolution mapping of tissue-related arrhythmias ([@bib8], [@bib36]). Moreover, the human origin of our cardiac cell sheets may be advantageous over the conventional animal-derived *in vitro* models such as neonatal rat ventricular myocyte cultures because of the significant interspecies differences in the expression of relevant cardiac ion channels ([@bib37]). For example, it was reported that I~Kr~ blockers could terminate spiral waves in cardiomyocyte monolayers derived from hPSCs but not from neonatal rat cardiomyocytes ([@bib16]). This difference stems from the important role of I~Kr~ in repolarization in the human, but not in the rodent, heart ([@bib37]).

The circular hiPSC-CCSs model established here follows similar efforts in the field ([@bib10], [@bib16], [@bib18], [@bib19]) and was made possible by advancements in hPSC cardiomyocyte differentiation protocols ([@bib3], [@bib27]), allowing the derivation of large quantities of relatively pure populations of cardiomyocytes. In this study, we generated confluent, high-density hiPSC-CCSs with high cardiomyocyte content. These characteristics are important since previous studies showed that arrhythmia inducibility was inversely correlated with cell seeding density ([@bib16]) and cardiomyocyte content ([@bib41]), probably because myocyte scarce areas may act as anatomical substrates for complex and fractionated conduction and reentry.

Previous reports have examined similar cell sheets by mapping of calcium transients or APs using calcium or VSDs respectively ([@bib8], [@bib16], [@bib18], [@bib19]). A major limitation of using such dyes for optical mapping of cardiac cultures is their phototoxicity, which can affect cell viability and potentially alter the studied electrophysiological properties ([@bib23], [@bib24], [@bib31]), thereby significantly hampering long-term or repeated mapping. Importantly, we demonstrated that hiPSC-CCSs expressing ArcLight alone did not suffer from phototoxic effects following continuous excitation. This is opposed to sheets loaded with Di-4-ANBDQBS alone or together with ArcLight, which displayed augmented cellular damage in the illuminated centers.

One limitation of ArcLight is its relatively slow kinetics at high frequencies, leading to alterations in the fluorescent representation of phase 0 of the AP ([@bib15], [@bib20]). Since activation mapping is based on measuring LAT from the timing of phase 0 of the optical APs at each sampled pixel, this limitation could lead to inaccurate maps. When comparing the ArcLight-based optical signals with Di-4-ANBDQBS, which does not interfere with ArcLight spectrum ([@bib24]), we could detect the typical two-stage exponential kinetics of ArcLight, characterized by an initial rapid phase that closely matches the VSD signal and a second phase where the ArcLight signal is significantly lagging behind the VSD. By targeting the initial rapid stage of phase 0 (timing of the maximal first derivative of the signal) to determine LATs, we could derive values that were almost identical between the ArcLight and VSD signals, including when using different signal-acquisition sampling rates. This allowed derivation of ArcLight-based activation and CV maps that matched those obtained by Di-4-ANBDQBS.

Based on these findings we reasoned that ArcLight-based mapping could enable reliable, long-term, and repeated phenotyping of the same specimens, allowing the study of long-term electrical remodeling processes and chronic effects of drugs or other interventions. Consequentially, by subjecting the same ArcLight-hiPSC-CCSs to repeated imaging over weeks, we identified the continuous shortening of APD over time and gradual increases in CV. To address the mechanisms underlying such CV changes, we focused on quantifying Cx43 expression (as a surrogate for changes in cellular coupling) and on Na^+^ current recordings (as a surrogate for membrane excitability). Our results did not show any consistent changes in the expression of Cx43 but did reveal a significant increase in Na^+^ current density over time in the hiPSC-CCSs. It is worth mentioning, however, that this increased CV is still one magnitude slower than in the native myocardium.

To demonstrate the utility of the ArcLight-hiPSC-CCS model for drug testing, we evaluated four different pharmacological agents and observed the expected dose-response effects on conduction slowing induced by suppression of gap-junction coupling (carbenoxolone) or membrane excitability (lidocaine and quinidine) and APD prolongation (dofetilide and quinidine). Moreover, the ability to use the suggested model for repeated long-term phenotyping studies can maximize the drug-screening potential, as the same specimens can be used for multiple "drug/wash" cycles to evaluate different drugs.

Importantly, while assays at the cellular level can detect APD prolongation ([@bib4], [@bib20], [@bib23]), they lack the ability to address the degree of its heterogeneity and spatial distribution in the tissue and cannot predict drug effects on conduction. Since both CV and APD (as a surrogate for refractory period) play a role in determining the tissue wavelength (a key parameter inversely proportional to arrhythmogenic susceptibility), APD alone is not sufficient to determine the tissue\'s arrhythmogenic propensity.

A potential application of the hiPSC technology is in the field of safety pharmacology and specifically for "QT screening", since drug-induced APD prolongation causing life-threatening ventricular arrhythmias (TdP) is the leading cause for withdrawal of approved drugs from the market ([@bib29]). Recent studies focused on developing screens to identify drug-induced APD prolongation using cardiomyocytes derived from human embryonic stem cells ([@bib4], [@bib20]) or hiPSC ([@bib21], [@bib31], [@bib33], [@bib42]). These studies, utilizing optical recordings ([@bib23]) or intracellular ([@bib21]) and extracellular ([@bib4], [@bib33]) electrophysiological measurements, primarily focused on the use of single-cell or small cell clusters and were able to detect APD prolongation and even EADs and TA. While APD prolongation, EADs, and TA are prerequisites for development of pro-arrhythmia, they are not sufficient, since development of clinical TdP requires also the presence of the necessary substrate at the tissue level ([@bib1]).

Using continuous imaging of dofetilide-treated ArcLight-hiPSC-CCSs, we were able to map step by step the process of arrhythmia initiation and sustainment as a result of drug-induced APD prolongation ("TdP in the dish"). Our results highlight the importance of heterogeneity of repolarization in the mechanism of drug-induced arrhythmias. The development of dofetilide-induced APD prolongation and EAD/TA formation was necessary but not sufficient by itself to induce arrhythmia. The latter required, in addition, spatiotemporal repolarization heterogeneities, resulting in the presence of an already repolarized (and therefore excitable) tissue in close proximity to the site of EAD/TA formation, allowing the initiation and maintenance of complex reentrant activity.

We next demonstrated that clinically relevant interventions could prevent drug-induced arrhythmias in our model. Rapid pacing and magnesium sulfate are commonly used in the clinical management of TdP. Importantly, both treatments were also demonstrated to prevent dofetilide-induced EADs and TA and to eliminate the risk for TdP in our hiPSC-CCSs model.

In addition to drug-related arrhythmias, we were also able to induce stable spiral waves by incremental electrical stimulation protocols. These arrhythmias were then mapped and analyzed either as dynamic displays, activation maps, or by the use of phase mapping. The latter approach facilitates detailed analysis of rotor stability parameters (such as curvature and SP meandering). Since rotors may play an important role in cardiac fibrillation ([@bib28]), the development of our human model may provide insights into the mechanisms of their initiation and perpetuation as well as for monitoring the effects of different therapeutic modalities. Consequentially, we were able to use our model to demonstrate the ability to interrupt and terminate rotor activity by clinically relevant interventions such as overdrive pacing and electrical cardioversion.

Among the limitations of the hiPSC-CCS model is the relatively immature state of hiPSC-CMs ([@bib38]), which is an important shortcoming of the field in general. An obvious consequence is the slow CV observed within our tissues. Our measured CV values (2--7 cm/s) are in the range of some of the studies using hPSC-CM-derived tissues ([@bib16], ∼2--12 cm/s; [@bib18], ∼5.4 cm/s) but slower than values reported in others ([@bib40], ∼13--18 cm/s). This variability in CV values may stem from differences in the hPSCs lines used, in the cardiomyocyte differentiation protocols, in the culture density and cardiomyocyte content, in the culture-media used, and in the maturation stage of the hPSC-CMs. One advantage of the observed slow CV is that it leads to a shortened wavelength, which in turn can facilitate arrhythmia induction in smaller tissues, allowing down-scaling the size of the hiPSC-CCSs.

Although shown to be suitable for mapping in the current experimental conditions, the slow kinetics of ArcLight ([@bib15]) may hinder perfect recapitulation of the AP morphology. This shortcoming may be solved in the future by using GEVIs with faster kinetics, such as ASAP1 ([@bib32]) and Arch(D95N) ([@bib17]). Lastly, our model utilizes an already established transgenic hiPSC line that expresses ArcLight constitutively ([@bib31]). Generating multiple stable hiPSC lines to model different disease- or patient-specific abnormalities may not be practical. This limitation may be solved by using transient lenti- or adeno-viral-based transductions of the differentiating cardiomyocytes.

In conclusion, we have established a platform for generation and mapping of 2D hiPSC-CCSs expressing a GEVI. This robust and promising platform can be widely utilized for safety pharmacology, studying arrhythmia mechanisms, and for testing various antiarrhythmic approaches.

Experimental Procedures {#sec4}
=======================

[Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} section is available online.

Cardiomyocyte Differentiation of the ArcLight-hiPSCs {#sec4.1}
----------------------------------------------------

We utilized a transgenic hiPSC line that stably expresses ArcLight ([@bib31]). Cardiomyocyte differentiation was induced using the monolayer differentiation system with a chemically defined medium supplemented with human albumin and ascorbic acid ([@bib3]).

Generation of the hiPSC-CCSs {#sec4.2}
----------------------------

hiPSC-CMs at d8--14 were enzymatically dissociated and seeded as circular cell sheets (∼0.5 cm diameter) on Matrigel-coated culture plates (Corning) at a seeding density between 38,000 and 56,000 cells/mm^2^ (0.75--1.1 million cells in 50 μL drop, [Figure S1](#mmc1){ref-type="supplementary-material"}B). Tissues were cultured in RPMI/B27 containing 1% penicillin/streptomycin and blebbistatin (5 μmol/L).

Optical Mapping {#sec4.3}
---------------

The optical mapping setup consisted of a high-speed EM-CCD (electron multiplying charge coupled device) camera (Evolve 512Delta, Photometrics, 512 × 512 pixels) mounted on a fluorescent macroscope (MVX10, Olympus). Both ArcLight and Di-4-ANBDQBS containing specimens were excited using light-emitting diodes (X-Cite TURBO, Excelitas Technologies) with peak wavelengths at 475 and 630 nm, respectively. For ArcLight recordings, emission was passed through 495 nm long-pass dichroic mirror and filtered using 525/50 nm band-pass filter. A 660 nm long-pass dichroic mirror and 665 nm long-pass filter were used for Di-4-ANBDQBS recordings (all from Chroma). Fluorescence was acquired at 4 × 4 binning and a sampling interval of ∼3.847 ms.

Acquisition and Analysis of Electrophysiological Parameters {#sec4.4}
-----------------------------------------------------------

OMProCCD ([@bib12]), a custom-designed software, was kindly provided by Prof. Bum-Rak Choi (Brown University) and was utilized for acquisition and analysis. For generation of activation maps, LAT at each pixel was determined from the optical signals as the time point of the maximal first derivative (dF/dt)~max~. APD~80~ was defined as the time interval between the LAT and the time point of 80% repolarization. Activation and APD~80~ maps were displayed as color-coded maps.

Comparison of ArcLight versus Di-4-ANBDQBS Mapping {#sec4.5}
--------------------------------------------------

ArcLight-hiPSC-CCSs were loaded for 7 min with RPMI/B27 medium containing 15 μg/mL (26.3 μmol/L) Di-4-ANBDQBS (purchased from Prof. Leslie Loew). Both reporters were imaged by alternating filter cubes ([Figure S2](#mmc1){ref-type="supplementary-material"}A). To compare APD~80~ and MLCV values derived using the two reporters, we evaluated cultures at different developmental stages (6-- 35 days) and at various pacing frequencies (CLs, 300--2,000 ms) ([Figure S2](#mmc1){ref-type="supplementary-material"}A).

Drug Studies {#sec4.6}
------------

Carbenoxolone (50 μmol/L), quinidine (0.1, 0.3, 1, 3, 10, and 30 μmol/L), lidocaine (1, 3, 10, 30, 100, and 300 μmol/L) stock solutions were dissolved in H~2~O, while dofetilide (0.3, 1, 3, 10, 30, and 100 nmol/L \[dose-response\], 50 nmol/L \[drug-induced pro-arrhythmia\]) stock solution was dissolved in DMSO (all from Sigma-Aldrich). All recordings were performed 10 min after each dose application, except for carbenoxolone (30 min).

Electrical Stimulation and Arrhythmia Induction {#sec4.7}
-----------------------------------------------

A stimulus isolation unit (SIU-102, Warner Instruments) was utilized to deliver 5 ms pulses through a platinum iridium electrode (Alpha-Omega) or custom-made platinum electrodes positioned close to the tissue edge ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Arrhythmia inducibility was evaluated using a three-step pacing protocol: (1) incremental pacing frequency until loss of capture or induction of arrhythmia; (2) burst pacing for 3 s; and (3) direct current injection for up to 3 s.

Phase Mapping {#sec4.8}
-------------

Phase maps and related rotor biophysical parameters were computed similarly to that described previously ([@bib7], [@bib11], [@bib14], [@bib28]) using a semi-automated custom-written MATLAB script that generated color-coded phase maps. The SP was identified as the point where all phases of the AP conjoin ([@bib14]), then the meandering pathway of the SP (six steps of one rotor rotation) was calculated. Rotor radius, which is inversely proportional to the rotor\'s curvature, was defined as previously described ([@bib11]).

Experiment Solutions {#sec4.9}
--------------------

Experiments were performed at 34°C using Tyrode\'s solution containing (in mmol/L): NaCl, 140; KCl, 5.4; CaCl~2~, 1.8; MgCl~2~, 1.0; HEPES, 10; and glucose, 10 (pH 7.4 with NaOH). Prolonged experiments were performed in RPMI/B27 culture medium incubated with 95% air and 5% CO~2~.

Statistical Analysis {#sec4.10}
--------------------

Data are presented as mean ± SEM. Paired t test was used to compare ArcLight- and Di-4-ANBDQBS-derived SNR values and changes in mean MLCV values following carbenoxolone (50 μmol/L) administration. Repeated-measurements one-way ANOVA followed by Tukey post-hoc multiple-comparison analysis was carried out for comparison of mean MLCV and/or APD~80~ values in (1) repeated phenotyping experiments over time, (2) pharmacological dose-response experiments, and (3) the dofetilide ± MgSO~4~ APD studies. Repeated-measurements two-way ANOVA followed by Sidak post-hoc analysis was carried out for Na^+^ activation currents analysis. Kruskal-Wallis test followed by Dunn\'s multiple-comparison test was carried out for arrhythmogenicity score comparisons.
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